# HPAP -190 Donor Summary

| *HPAP* | *190* | *UNOS* | |
|---|---|---|---|
| **Recovery OPO** | California (CAOP) | **Allocation Via** | UPENN ☐ nPOD ☒ |
| **Age (years)** | 23 | **DCD** | YES ☐ NO ☒ |
| **Race** | Caucasian/Hispanic Biracial | **DBD** | YES ☒ NO ☐ |
| **Sex** | M ☐ F☒ | **Admission to Cross Clamp** | 364 Hours 15 Mins. |
| **ABO (Rh)** | O positive | **Cross Clamp Time** | 4/26/25 04:43 ET |
| **BMI (Kg/m²)**<br>**Weight (kg)**<br>**Height (cm)** | 19.65<br>46.40<br>153.00 | **Cold Ischemia Time*** | 13 Hours 17 Mins. |
| **Cause of Death** | Cerebrovascular/Stroke | **Preservation Solution** | UW ☐ HTK☐<br>**NA** |
| **Mechanism of Injury** | Intracranial Hemorrhage /Stroke | **Organs Recovered** | Heart ☐ Kidney ☒<br>Lung ☐ Pancreas ☒<br>Liver ☒ Intestine ☐ |
| **Cardiac Arrest/Downtime** | Yes ☒<br>No ☐ | **Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity:** | ☐ Hours ☐ Mins.<br>**NA** |
| **CPR / Time** | Yes ☐<br>No ☐<br>Chest Compressions unknown duration | **Organs Discarded** | Heart ☐ Kidney ☐<br>Lung ☐ Pancreas ☐<br>Liver ☐ Intestine ☐ |
| **Total Est. Downtime** | unknown duration | **Blood Culture** | No growth at 5 days |
| **Date /Time of Admission** | 04/10/2025 21:28 PDT<br>04/11/2025 00:28 EDT | **PHS High Risk** | YES ☐ NO ☒ |
| | | **Acute Lung Injury** | Persistent asymmetric bilateral lung infiltrates suggestive of pneumonitis or edema. |

***Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.**

# HPAP -190 Donor Summary

## Medical History:

| | | Duration | Medications | Compliance |
|---|---|---|---|---|
| **Type of Diabetes** | None | ----- | ----- | ----- |
| **History of cancer** | ----- | ----- | ----- | ----- |
| **CAD** | ----- | ----- | ----- | ----- |
| **Hypertension** | ----- | ----- | ----- | ----- |
| **Hyperlipidemia** | NA | ----- | ----- | ----- |
| **Autoimmune disease** | | | | |
| **Family History** | CAD ☐ | Diabetes ☐ | Auto immune disease ☐ | Others: |
| **Surgical History:** | NA | | | |
| **Comments:** | Medical Hx: Childhood meningitis leading to hydrocephalus, VP shunt 2008 with revision surgery in 2018, Epilepsy | | | |

## Hemodynamic Profile

| | | |
|---|---|---|
| **Average BP During Hospitalization (mmHg)** | 96/65 | |
| **Average Low BP During Hospitalization** | NA | **Duration: NA** |
| **Average BP in OR (mmHg)** | NA | |
| **Average Low BP in OR (mmHg)** | NA | **Duration: NA** |
| **Average HR in OR (bpm)** | NA | |
| **ABG-pH range** | 7.11 - 7.67 | |

## INTERVENTION

## Blood Products/Meds Transfused Before Organ Recovery

| Product | Amount (ml) | Units | Total (ml) |
|---|---|---|---|
| **Fresh Frozen Plasma** | ----- | ----- | ----- |
| **PRBCs** | 350.00 | 2 | 700.00 |
| **Platelets** | ----- | ----- | ----- |
| **Norepinephrine (Levophed)** | ----- | 1.00 - 16.00 mcg/min started started 5 days before organ recovery | |
| **Vasopressin** | ----- | 0.030 units/min started started 5 days before organ recovery | |
| **Neo-Synephrine** | ----- | 20.00 – 200.00 mcg/min started started 5 days before organ recovery | |
| **Epinephrine** | ----- | ----- | ----- |
| **Phenylephrine** | ----- | ----- | ----- |
| **Dopamine** | ----- | ----- | ----- |

# HPAP -190 Donor Summary

## Blood Products/Meds Transfused Intraoperative

| Product | Amount (ml) | Units | Total (ml) |
|---|---|---|---|
| **Fresh Frozen Plasma** | NA | NA | NA |
| **PRBCs** | NA | NA | NA |
| **Platelets** | NA | NA | NA |
| **Norepinephrine (Levophed)** | NA | NA | NA |
| **Vasopressin** | NA | NA | NA |
| **Neo-Synephrine (phenylephrine)** | NA | NA | NA |
| **Epinephrine** | NA | NA | NA |
| **Dopamine** | NA | NA | NA |
| **Heparin** | ----- | 30,000 | ----- |

## Initial Autoantibody Screening (nPOD): ELISA

| **GAD-65** | **IA-2** |
|---|---|
| **GADA : Negative** | **Positive (IA2A- 1.8)** |

## Confirmatory results: Radioimmuno Assay (RIA)

| | **GAD-65 (unit/ml)** | **IA-2 (unit/ml)** | **Insulin AAB (unit/ml)** | **ZnT8 (unit/ml)** |
|---|---|---|---|---|
| **Results** | 0 | 0 | -0.001 | -0.002 |
| **Cut-off values** | 20 | 5 | 0.01 | 0.02 |

*Sample obtained at time of organ recovery.

| | **C-peptide (ng/ml)** | **Proinsulin** |
|---|---|---|
| Results | 11.81 | NA |

*Sample obtained at time of organ recovery.

## HLA (OPO)*

| **Class 1** | **A** | 2 | 3 | **Class II** | **DR** | 17 | 8 |
|---|---|---|---|---|---|---|---|
| | **B** | 18 | 35 | | **DR51** | N-Negative | N-Negative |
| | **C** | 04 | 05 | | **DR52** | 52 | N-Negative |
| | **Bw4** | Negative | | | **DR53** | N-Negative | N-Negative |
| | **Bw6** | Positive | | | **DQB1** | 2 | 4 |
| | [redacted] | | | | **DQA1** | 04 | 05 |
| | | | | | **DPB1** | 04:01 | 04:02 |
| | | | | | **DPA1** | 01 | 01 |
| **Comment:** | | | | | | | |

# HPAP -190 Donor Summary

## Confirmatory HLA (UPENN)*

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Class 1** | **A** | 02:01 | 03:01 | **Class II** | **DRB1** | 03:01 | 08:02 |
| | **B** | 18:01 | 35:12 | | **DRB3** | 02:02 | ----- |
| | **C** | 04:01 | 05:01 | | **DRB4** | ----- | ----- |
| | | | | | **DRB5** | ----- | ----- |
| | | | | | **DQB1** | 02:01 | 04:02 |
| | | | | | **DQA1** | 04:01 | 05:01 |
| | | | | | **DPB1** | 04:01 | 04:02 |
| | | | | | **DPA1** | 01:03 | ----- |

*HLA typing performed using NGS
DPB1*126:01,105:01 allele combination was not ruled out.

## Infectious Disease Serology

| | | Hemo/Plasma Dilution Status | |
|---|---|---|---|
| **Test** | **Result** | **Qualified** | **Non-Qualified** |
| **EBV IgG** | **Positive** | ✓ | - |
| **EBV IgM** | Negative | ✓ | - |
| **CMV IgG** | Negative | ✓ | - |
| **CMV IgM** | Negative | | |
| **HBcAb** | Non-Reactive | ✓ | - |
| **HBsAg** | Non-Reactive | ✓ | - |
| **HCV Ab** | Non-Reactive | ✓ | - |
| **HIV I/II** | ND | – | - |
| **HIV Ag/Ab Combo** | Non-Reactive | ✓ | - |
| **Syphilis** | Non-Reactive | ✓ | - |
| **Procleix Ultrio** | ND | – | - |
| **Ultrio HBV (HBV NAT)** | Non-Reactive | ✓ | - |
| **Ultrio HCV (HCV NAT)** | Non-Reactive | ✓ | - |
| **Ultrio HIV (Ultrio Elite HIV-1/2)** | Non-Reactive | ✓ | - |
| **Toxoplasma Ab** | Negative | ✓ | - |
| **T. Cruzi** | Negative | ✓ | - |
| **WNV NAT, WNV IgM** | Negative | ✓ | - |
| **Strongyl IgG** | Negative | ✓ | - |
| **Chagas (EIA)** | Non-Reactive | | |
| **SARS-CoV-2** | Negative | ✓ | - |

# HPAP -190 Donor Summary

## Laboratory Panel

| | Initial | Peak | Terminal |
|---|---|---|---|
| **Na (mEq/L) (135-145)** | 142 | 154 | 138 |
| **Creatinine (<1.5)** | 0.63 | 1.44 | 1.44 |
| **Glucose (mg/dL) (60-150)** | 134 | 266 | 154 |
| **HbA1C%** | **5.5** | ----- | ----- |
| **Total bilirubin (0-1.0)** | 0.7 | 1.3 | 1.2 |
| **SGOT (AST) (0-40)** | 44 ( | 158 | 157 |
| **SGPT (ALT) (5-35)** | 26 | 103 | 35 |
| **Alkaline phosphatase (45-110)** | 43 | 64 | 55 |
| **Serum Amylase (23-851)** | 48 ) | 222 | 204 |
| **Serum Lipase (0-80)** | 24) | 34 | 34 |
| **WBC (THO/uL) (4.5-11.0)** | 8.7 | 17.7 | 14.5 |
| **Hgb (g/dL) (12-16)** | 11.6 | 12.8 | 8.6 |
| **Platelets (THO/uL) (150-350)** | 250 | 250 | 167 |
| **INR (<2.0)** | 1.18 | 1.28 | 1.26 |

## Urinalysis

| | 1st | 2nd | 3rd | 4th - 8th |
|---|---|---|---|---|
| **Glucose** | **70** | Negative | Negative | Negative |

## Medications During Hospitalization

| | | | |
|---|---|---|---|
| **Steroids**** | Solu-Medrol | | |
| **Diuretics** | Lasix 60.00 mg / 6.00mL | | |
| **T3 Protocol** | ----- | | |
| **T4 Protocol*** | ----- | | |
| **Insulin**** | 1.5 – 15 units /hr. for the duration of 59 hrs. | | |
| **Antihypertensive** | ----- | | |
| **Vasodilators** | ----- | | |
| **DDAVP**** | ----- | | |
| **Total parenteral nutrition** | ----- | | |
| **Other** | Zosyn 3.375 Q8 , Vancomycin 750mg, GIK 13.90mL, NS, KCL 40.00 meq / 100.00mL, Thiamine 100 mg, Albumin 25%, Vancocin, Magnesium sulfate, Methylene Blue, Dobutamine 0.750 mcg/kg/min/1.03mL, Erythromycin | Specify | |

*T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

*Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015:7 17-27.*

** Excluding T4 Protocol